Opinion

Video

CLEAR Trial: Lenvatinib plus Pembrolizumab in Advanced RCC

Experts highlight key clinical updates from the CLEAR trial presented at the 2023 IKCS: North America congress, assessing lenvatinib plus pembrolizumab in patients with advanced RCC.

This is a video synopsis/summary of a Post Conference Perspectives featuring Brian Rini, MD, and Hans Hammers, MD, PhD.

Rini and Hammers discuss recent data presented at the 2023 International Kidney Cancer Symposium (IKCS) that examined the efficacy of lenvatinib plus pembrolizumab versus ipilimumab plus nivolumab. The study used a statistical matching analysis to indirectly compare outcomes between the regimens. It suggested that while overall survival was comparable, lenvatinib/pembrolizumab may confer improved progression-free survival over ipilimumab/nivolumab.

However, Rini notes such cross-trial comparisons should be viewed skeptically, especially when industry-sponsored to favor 1 regimen. He believes the analysis shows what was already expected: lenvatinib/pembrolizumab has superior response rates and progression-free survival compared with ipilimumab/nivolumab. But the relevance for individual patients is debatable, considering the importance of other end points like long-term survival. Hence this type of analysis is unlikely to significantly impact treatment selection decisions. It does reinforce the known efficacy of lenvatinib/pembrolizumab for early tumor outcomes based on the CLEAR trial.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Charles B. Nguyen, MD
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.
Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.